SOURCE: Marina Biotech, Inc.

Marina Biotech, Inc.

December 13, 2010 09:00 ET

Marina Biotech, Inc. to Participate in RodmanTV Analyst Discussion

BOTHELL, WA--(Marketwire - December 13, 2010) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today that it will participate in an analyst discussion hosted by RodmanTV on Monday, December 20, 2010, at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time) at Rodman & Renshaw's offices in New York City. J. Michael French, Marina Biotech President and Chief Executive Officer, will participate in the discussion with Simos Simeonidis, Managing Director and Senior Biotechnology Analyst at Rodman & Renshaw, LLC. 

Parties interested in participating in the live conference call can contact Melissa Woodson, Rodman & Renshaw, at 212.430.1782 for specific details and availability. Institutional investors are invited to access the video replay of the presentation at the RodmanTV website: http://www.rodm.TV.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech's goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Contact Information

  • Contact:
    Marina Biotech, Inc.:
    Pete Garcia
    Chief Financial Officer
    (425) 908-3603